Primary melanoma of the pineal gland is a rare disease entity with an overall poor prognosis. Limited data exist to appropriately guide treatment decisions. Historical case reports have showed some success using a combination of surgical resection, radiotherapy, and chemotherapy, but long-term survival has been exceedingly rare. This report presents a female patient with a primary pineal melanoma who underwent subtotal resection followed by adjuvant focal radiation to the residual tumor. Immunohistochemistry identified a strong positivity for PD-L1 (70%). After radiation, systemic therapy with pembrolizumab was initiated with the plan to treat until progression. She has now completed 33 cycles of pembrolizumab without interruptions, complications, or disease progression. At the time of writing, the patient has had an excellent clinical outcome, with a durable near-complete response of >138 weeks. To our knowledge, this is the first patient with a pineal melanoma to be managed by targeting PD-L1. Furthermore, she has achieved the second longest overall survival and the longest progression-free survival reported in the literature.
Submitted March 25, 2019; accepted for publication June 25, 2019.
Disclosures: The authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.
Correspondence: Justin Famoso, MD, Department of Radiation Oncology, The University of Arizona, 3838 North Campbell Avenue, Building 2, Tucson, AZ 85719. Email: email@example.com
WendelC, KaechDL, WoodtliM. Primary malignant melanoma in the pineal region: case report and literature review. J Neurol Surg A Cent Eur Neurosurg 2018;79:344–352.2964985110.1055/s-0038-1639504)| false
JetschkeK, ViehwegerH, FreesmeyerM, . Primary pineal malignant melanoma with B-Raf V600E mutation: a case report and brief review of the literature. Acta Neurochir (Wien) 2015;157:1267–1270.10.1007/s00701-015-2427-325976339)| false